On June 22, 2002 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK (Tazemetostat), a new oral treatment for adult with relapsed/refractory follicular lymphoma whose tumors are positive for an EZH2-mutation as detected by an U.S. Food and Drug Administration (FDA)-approved test and who have received at least two prior systemic therapies or for adult patients with relapsed/refractory follicular lymphoma who have no satisfactory alternative treatment options (Press release, Onco360, JUN 22, 2020, View Source [SID1234561343]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The approval of TAZVERIK as a treatment option for patients with relapsed/refractory follicular lymphoma is an important advancement in fighting this devastating disease," said Paul Jardina, President and CEO, Onco360. "As a specialty oncology pharmacy, we are committed to improving the lives of cancer patients suffering from follicular lymphoma."
Follicular lymphoma is the second-most common type of non-Hodgkin lymphoma and is considered to be indolent, yet incurable. According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, approximately 12,600 patients are diagnosed with follicular lymphoma on an annual basis. When considering all stages of the disease, follicular lymphoma has a five-year overall survival of 89%. Approximately 30% of follicular lymphoma patients are found to have EZH2-mutations.
TAZVERIK is manufactured by Epizyme, a global, commercial-stage, research-based biotechnology company, and was previously approved by the FDA in January 2020 for the treatment of adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The FDA’s approval of TAZVERIK for relapsed/refractory follicular lymphoma is based on the results of two open-label, single-arm cohorts of the Phase I/II E7438-G000-101 clinical trial (NCT01897571) which demonstrated a 69% overall response rate in EZH2-mutant relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy and a 34% overall response rate in EZH2-wild-type relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy. For full prescribing information, visit TAZVERIK.com.